

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of treating and/or preventing a cranial/brain trauma and/or cerebral ischemia comprising the step of administering to a subject in need thereof a medicament comprising an active ingredient selected from the group consisting of: Use of frankincense, frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives, and the physiologically acceptable salts thereof of said derivatives, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative, and or a boswellic acid-containing vegetable preparation for the production of a medicament for the prophylactic and/or therapeutic treatment of cranial/brain trauma and/or cerebral ischemia.
2. (Currently Amended) The method Use according to claim 1, wherein the cerebral ischemia occurs as a result of apoplexy, cardiac infarction or an operation.
3. (Currently Amended) The method Use according to claim 1 or 2, wherein the active ingredient comprises characterized in that frankincense or a boswellic acid-containing vegetable extract is used.
4. (Currently Amended) The method Use according to claim 1 or 2, wherein the active ingredient is selected from the group consisting of characterized by using a keto-boswellic acid, in particular 3-O-acetyl-11-keto- β -boswellic acid, or 11-keto- β -boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative, and or a keto-boswellic acid-containing vegetable extract for the production of a medicament.

5. (Currently Amended) The method Use according to claim 1 or 2, wherein the active ingredient comprises characterized by using a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof ~~for the production of a medicament.~~
6. (Currently Amended) The method Use according to any of claims claim 1 to 3, wherein the active ingredient comprises characterized by using an extract from ~~a~~ the *Boswellia serrata* resin ~~for the production of a medicament.~~
7. (Currently Amended) A method of treating and/or preventing a cranial/brain trauma, cerebral ischemia and/or Alzheimer's disease comprising the step of administering to a subject in need thereof a medicament comprising an active ingredient selected from the group consisting of: ~~Use of~~ the hydrogenation products of frankincense extracts, substances contained in frankincense, their physiologically acceptable salts, their derivatives, ~~and~~ the physiologically acceptable salts ~~thereof of said derivatives~~, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative, ~~and~~ or a boswellic acid-containing vegetable preparation ~~for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease.~~
8. (Currently Amended) The method Use according to claim 7, wherein the medicament is used for preventing and/or treating Alzheimer's disease.
9. (Currently Amended) The method Use according to claim 7 or 8, wherein the active ingredient comprises characterized by using the ~~a~~ hydrogenation product of a boswellic acid-containing vegetable extract.

10. (Currently Amended) The method Use according to claim 7 or 8, wherein the active ingredient comprises characterized by using a hydrogenated extract from a the *Boswellia serrata* resin for the production of a medicament.

11. (Currently Amended) The method Use according to claim 7, wherein the active ingredient is selected from the group consisting of characterized by using the a hydrogenation product of boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative thereof, a salt of a boswellic acid derivative, and or a boswellic acid-containing vegetable preparation.

12. (Currently Amended) The method Use according to any of claims claim 7 to 11, wherein the active ingredient comprises hydrogenation product is dihydroboswellic acid.

13. (Currently Amended) The method Use according to claim 7 or 8, wherein the active ingredient comprises a characterized in that the hydrogenation product is selected from the group consisting of β-dihydroboswellic acid acetate, β-dihydroboswellic acid formate, β-dihydroboswellic acid methyl ester, acetyl-β-dihydroboswellic acid, α-dihydroboswellic acid, acetyl-α-dihydroboswellic acid and formyl-α-dihydroboswellic acid.

14. (Currently Amended) The method Use according to claim 7 or 8, wherein the active ingredient is selected from the group consisting of characterized by using a keto-dihydroboswellic acid, in particular acetyl-11-keto-β-dihydroboswellic acid, 11-keto-β-dihydroboswellic acid, or formyl-11-keto-β-dihydroboswellic acid, a physiologically acceptable salt of a keto-dihydroboswellic acid, a derivative of a keto-dihydroboswellic acid, a salt of a keto-dihydroboswellic acid derivative, and or a hydrogenated keto-boswellic acid-containing vegetable extract for the production of the medicament.

15. (Currently Amended) The method Use according to claim 7 or 8, wherein the active ingredient is selected from the group consisting of characterized by using a hydrogenation product of tirucallic acid, its-a salt of said hydrogenation product, or a derivative of said hydrogenation product or salt thereof, and or a hydrogenated tirucallic acid-containing vegetable extract ~~for the production of the medicament.~~

16. (Currently Amended) The method Use according to any of claims claim 1 to 15, wherein characterized in that the medicament is made formulated for the intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

17. (Currently Amended) The method Use according to any of claims claim 1 to 16, wherein characterized in that the medicament comprises is available as a tablet or solution.

18. (New) The method according to claim 7, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

19. (New) The method according to claim 7, wherein the medicament comprises a tablet or solution.